After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

A Merus drug, combined with Keytruda, shows preliminary survival gains in newly diagnosed metastatic head and neck cancer ...

The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Merck & Co has filed Keytruda in bladder cancer in the US, setting the scene for a battle with rivals Roche and Bristol-Myers Squibb. Bristol-Myers Squibb’s rival immunotherapy Opdivo (nivolumab ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...